logo

RBOT

Vicarious Surgical·NYSE
--
--(--)
--
--(--)
0.54 / 10
Underperform

Fundamental analysis of RBOT reveals significant challenges: net profit margin is -2972.64% and key profitability ratios are negative, placing the stock in low-performing quartiles. However, the Asset-MV factor shows a moderate positive score of 3, indicating some asset quality. Revenue growth is strong at 78.47% YoY, but this is offset by poor earnings conversion and negative cash flow ratios. The overall fundamental assessment is 'challenging,' with a 0.5/10 quality score.

Fundamental(0.54)SentimentTechnical

Analysis Checks(2/10)

Revenue-MV
Value-0.26
Score0/3
Weight11.58%
1M Return-2.92%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight5.35%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value78.47
Score0/3
Weight17.38%
1M Return-6.59%
Net cash flow from operating activities / Operating revenue (%)
Value-1513.77
Score0/3
Weight20.06%
1M Return-7.70%
Net income-Revenue
Value-0.17
Score1/3
Weight2.39%
1M Return-0.69%
Net profit margin (%)
Value-2972.64
Score0/3
Weight20.90%
1M Return-8.03%
Current assets turnover ratio
Value1.78
Score1/3
Weight5.82%
1M Return-1.72%
EBIT / Total operating revenue (%)
Value-3056.43
Score0/3
Weight19.77%
1M Return-7.44%
Asset-MV
Value-0.50
Score3/3
Weight-23.76%
1M Return5.62%
Net profit / Total operating revenue (%)
Value-2164.14
Score0/3
Weight20.50%
1M Return-7.85%
Is RBOT undervalued or overvalued?
  • RBOT scores 0.54/10 on fundamentals and holds a Premium valuation at present. Backed by its -130.51% ROE, 0.00% net margin, -0.26 P/E ratio, 1.00 P/B ratio, and 11.64% earnings growth, these metrics solidify its Underperform investment rating.